The mean serum TFF2 concentration in patients with gastric cancer was 1.08 ± 0.07 ng/ml (95% CI [0.93, 1.23]), which was significantly higher than those in CAG (0.86 ± 0.07 ng/ml, 95% CI [0.71, 1.00], P = 0.034), CNAG (0.64 ± 0.08 ng/ml, 95% CI [0.47, 0.81], P = 0.0011), and healthy (0.63 ± 0.05 ng/ml, 95% CI [0.53, 0.74], P < 0.0001) group. Here, TFF2 is linked to gastric cancer.